Biotech Values

[mcbio]

Re: Roche/ITMN HCV exclusivity deal

It also looks like Roche could have easily walked away from the agreement themselves so it looks like they may see some value in 191.

My understanding, based on prior discussions with Dew, is that Roche had an HCV exclusivity deal with ITMN and therefore could not just walk away from the partnership with ITMN if Roche ever wanted to license an outside HCV compound. I.e., Roche had to pay ITMN to terminate its HCV exclusivity deal with ITMN in order to have the freedom to license an HCV compound from another company.